scholarly journals The role of serum 25-hydroxyvitamin D, ionized calcium and phosphorus in breast cancer females: A case-control study

2015 ◽  
Vol 4 (2) ◽  
pp. 228 ◽  
Author(s):  
Nadia Abd El Moneim ◽  
Taha Hewala ◽  
Mona Rashad ◽  
Yousria Moussa ◽  
Nehal Abu-Samra ◽  
...  

<p><strong>Aim:</strong> To evaluate the diagnostic and prognostic value of serum 25- hydroxyvitamin D (25(OH) D), ionized calcium and phosphorus in comparison with serum CA15.3 as the most commonly used breast cancer marker.</p><p><strong>Participants and methods:</strong> This study was conducted on 45 breast cancer female patients with recently detected breast cancer before surgery and 45 apparently healthy female controls of matched age, menstrual and socioeconomic status as breast cancer patients group. Serum 25(OH) D, ionized calcium, phosphorus and CA15.3 were measured using ready-for-use commercially available kits.</p><p><strong>Results:</strong> Serum levels of 25(OH) D and ionized calcium in the breast cancer patients group were significantly lower than those of the control group, while serum levels of phosphorus and CA15.3 in breast cancer patients group were significantly higher than those of the control group. The area under the ROC curve for serum ionized calcium (81.7%) was significantly greater than that of 25(OH) D (75.3%), CA 15.3 (70.1%) and phosphorus (62.8%). The odd’s ratio of vitamin D was 0.0937 (95% CI=0.0311-0.2823), of ionized calcium was 0.0464 (95% CI=0.015-0.141) and of phosphorus was 2.6801(95% CI=1.1269- 6.3742) in breast cancer patients group. Serum phosphorus was significantly correlated with age and menopausal status of breast cancer patients.</p><p><strong>Conclusion:</strong> Our results suggest that serum ionized calcium and 25(OH) D were superior to serum CA15.3 and phosphorus for prediction of breast cancer. In addition, our results indicate that 25 (OH) D and calcium may decrease the risk for breast cancer incidence, while phosphorus may increase this risk. None of the assayed biomarkers has a prognostic role in breast cancer.</p>

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Abeer I Abd Elmagid ◽  
Hala Abdel Al ◽  
Wessam El Sayed Saad ◽  
Seham Kamal Mohamed

Abstract Background Breast cancer is the most common cancer among women and one of the most important causes of death among them.Angiogenesis is an important step for primary tumor growth, invasiveness, and metastases. Angiopoietins are well-recognized endothelial growth factors that are involved in angiogenesis associated with tumors. Aim To explore the diagnostic significance of serum angiopoietin-2 (Ang-2) in breast cancer and to evaluate its prognostic efficacy through studying the degree of its association with the TNM staging of the disease. Patients and Methods This study was conducted on (35) Egyptian female patients who were diagnosed as breast cancer according to histopathological examination of breast biopsy (Group 1, Breast Cancer Patients) and (25) female patients with benign breast diseases (Group II, Pathological Control Patients), in addition to (20) age - matched apparently healthy, free mammogram, females serving as healthy controls (Group III, Healthy Controls). For all participants, measurement of serum Ang-2 was done using enzyme linked immunosorbent assay (ELISA) technique. Results A highly significant increased levels of Ang-2 was observed in breast cancer patients when compared to healthy control group (Z = 4.95, p &lt; 0.01). However, no significant difference was observed in Ang-2 levels between breast cancer patients group and pathological control group (Z = 3.37, p &gt; 0.05). No significant difference was detected in Ang-2 levels in relation to TNM stage and histological grade. No significant correlation was found between Ang-2 levels and serum levels of CA15-3, hormone receptors, HER2/new receptor status (p &gt; 0.05, respectively). Conclusion This study revealed that Ang-2 serum levels were significantly increased in patient with breast cancer compared with healthy controls, indicating that high Ang-2 level is a promising non invasive biomarker for breast cancer diagnosis. However, no significant difference of Ang-2 levels was detected in relation of breast TNM staging in the population studied.


PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e86467 ◽  
Author(s):  
Liang Shi ◽  
Sarah Nechuta ◽  
Yu-Tang Gao ◽  
Ying Zheng ◽  
Tsogzolmaa Dorjgochoo ◽  
...  

Author(s):  
Noor Al-Ashkar ◽  
Almoutassem Billah Zetoune

Abstract Background Breast cancer is the most commonly occurring cancer in women worldwide. S100A14 is a novel important member of S100 proteins family. Its importance is due to its role in tumorigenesis and metastasis process. In this study, we aimed to determine serum levels of S100A14 protein in breast cancer patients and healthy individuals to know if it can be suggested as a new biomarker for breast cancer and to reveal whether it is correlated with cancer pathological features. Methods This cross-sectional study was performed in two groups: study group contains 46 breast cancer patients (29 metastatic and 17 non-metastatic) and control group contains 22 healthy women. Enzyme-linked immunoabsorbent assay was performed to determine S100A14 protein levels in samples. Pathological data were obtained for each patient. The data were statistically analyzed using Kruskal-Wallis H, Mann-Whitney U, and Spearman correlation tests. Results S100A14 serum levels were elevated in study group compared with control group (P < 0.05). S100A14 serum levels were significantly increased in distant breast cancer patients compared with regional breast cancer patients (P = 0.001). There was a strong positive correlation between serum S100A14 level and tumor grade (rs = 0.713, P < 0.001). Conclusion Our study indicated that S100A14 serum levels are elevated in breast cancer patients compared with control individuals. High S100A14 serum levels were correlated with poor tumor differentiation so it might have a prognostic significance for breast cancer tumors. The elevation of S100A14 levels in distant breast cancer patients suggests the ability of using serum S100A14 as a biomarker for detection of breast cancer metastasis.


2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 5-5
Author(s):  
S.A Ali ◽  
A.N El-Daly ◽  
A El-Sayed ◽  
H.G El-Shredy ◽  
G.A Fadaly

Introduction: The associations between programmed cell death ligand 1 (PD-L1) and the prognosis of various cancers have always been a research topic of considerable interest.However, the prognostic value of PD-L1 in breast cancer patients remains a controversial subject. We aimed to evaluate the role of programmed death-1 receptor and programmed death ligand-1 (PD-1/PD-L1) expressing lymphocytes, monocytes and granulocytes, as potential mechanism of immune escape in breast cancer patients. Also, serum levels of Bcl-2 were analyzed among patients with different stages of breast cancer. Material and Methods: The study was conducted on a total of seventy-five females; fifty-five of them represented the breast cancer females at early (24 females) and advanced (31 females) stages and 20 ages matched female donors represented the control group. Patients were recruited from the Cancer Research and Management Department, Medical Research Institute, Alexandria University. Venous blood samples obtained from all females under study were used for determination of PD-1/PD-L1 expression using flowcytometry technique and measurement of Bcl-2 serum levels using ELISA technique. Results: Significantly higher expression levels of PD-L1 were found in patients with positive lymph node, advanced tumor stage, histological grade II, tumor size T2, ER, PR, Her-2 negativity and TNBC subtype. Whilst a general increase in PD-1 positive expression between the breast cancer patients and control group regarding percentage and MFI of positive PD-1 expressing monocytes and granulocytes. Also, the results showed a highly significant association between PD-1+ and PD-L1+ expression in early and advanced breast cancer patients (p<0.0001). There was a significant increase in the mean of Bcl-2 serum concentration in patients compared to healthy individuals. Finally, the results showed that Bcl-2 serum concentration correlated positively with positive PD-L1+ expressing granulocytes. While the correlation between serum Bcl-2 and PD-1+ expressing lymphocytes, monocytes and granulocytes did not show any statistical significance. Conclusions: Our study suggested that PD-L1 could serve as an important target for antibody based immunotherapies, especially in the TNBC, where treatment options are limited. The direct correlation between PD-L1+ expression and serum Bcl-2 concentration may explore a role of apoptotic machinery in the pathogenesis of breast cancer.


Nutrients ◽  
2018 ◽  
Vol 11 (1) ◽  
pp. 37 ◽  
Author(s):  
Rihwa Choi ◽  
Min-Ji Kim ◽  
Insuk Sohn ◽  
Serim Kim ◽  
Isaac Kim ◽  
...  

The relationships between serum levels of trace elements and breast cancer remain relatively unknown. In this study, we investigate serum levels of seven trace elements in Korean breast cancer patients compared to controls without breast cancer. Serum trace element levels were determined using inductively coupled plasma mass spectrometry in Korean breast cancer patients before initiation of breast cancer treatment. Korean females without breast cancer served as a control group. Trace element levels were measured in the discovery cohort (n = 287) and were validated in an independent cohort (n = 142). We further investigated possible associations between trace element levels and the presence of lymph node metastasis, distant metastasis, or triple-negative breast cancer among breast cancer patients in subgroup analyses. Serum manganese and molybdenum levels were significantly higher (p < 0.05) in breast cancer patients than in controls. Serum copper levels were significantly higher in breast cancer patients with distant metastasis, while selenium levels were significantly lower. Other trace elements were neither significantly different between breast cancer patients and controls nor between subgroups of breast cancer patients. Our study provides insights about the potential roles and impacts of trace elements through an assessment of the associations between trace elements and breast cancer.


2016 ◽  
Vol 9 (1) ◽  
pp. 1 ◽  
Author(s):  
Safaa Sabri Najim

In the breast cancer significant differences occurs in the normal distribution of the trace elements, playing an important role in carcinogenic process. The aim of this study was to investigate the serum levels of some trace elements (Chromium, Cadmium, Manganese, Cobalt, Nickel, Selenium, Zinc, Iron, Copper and Magnesium) by using flame atomic absorption spectroscopy (FAAS). The present study included 150 females, the participates were divided into two main groups, control group which consisted of 75 apparently healthy females, 75patients with breast cancer group .The serum levels of Chromium (tcal2.9631 ,ttab1.960), Cadmium (tcal2.0798 ,ttab1.960), Manganese (tcal18.5676, ttab1.960), Selenium (tcal2.2759,ttab1.960), Iron (tcal2.9296,ttab1.960), Copper (tcal4.0869, ttab1.960),Magnesium (tcal2.6648, ttab1.960), Cobalt (tcal3.8615 , ttab1.960) and Zinc (tcal7.0160, ttab1.960) were statistically significant higher in the breast cancer patients group than the control group. Similarly, Nickel (tcal1.5988,ttab1.960) levels showed significant lower level in breast cancer patients group. On the other hand, the higher levels of trace elements could lead to formation of free radicals or other reactive oxygen species. The evaluation of these trace elements in serum maybe used as helpful tool in diagnosis of the breast cancer.


2017 ◽  
Vol 14 (2) ◽  
pp. 56
Author(s):  
Amilia Yuni Damayanti ◽  
Dono Indarto ◽  
Brian Wasita ◽  
Tonang Dwi Ardyanto

Background: Breast cancer is the most common malignancy in women in the world. Vitamin D helps control the majority of gene expression in female reproductive tissues. Body mass index (BMI) influences the bioavailability of vitamin D. Diet is one of the main sources of vitamin D and it is directly converted into 25-hydroxyvitamin D [25 (OH) D] in the liver.Objective: This study aimed to analyze the relationship between BMI and vitamin D intake and 25 (OH)D serum in patients with breast cancer.Method: Analytic observational with cross sectional design was used in this study. A total of 37 breast cancer patient visited Dr. Moewardi Hospital in Surakarta was selected as research subjects using a purposive sampling technique. BMI data was obtained by measuring body weight and height. Vitamin D intake was determined using 1 x 24-hour food recall and semi-quantitative food frequency questionnaire. While, 25(OH)D serum was measured using enzyme-linked immunoabsorbent assay. Data analysis used Spearman correlation test.Results: The averages of BMI, vitamin D intake and 25(OH)D serum of breast cancer patients were 21.96±3.63 kg/m², 3.50±3.30 µg/day and 16.01±14.67 ng/mL respectively. Most breast cancer patients had less vitamin D intake and 25(OH)D serum deficiency. There was a weak relationship between BMI (r=0.188, p=0.266) and vitamin D (r=0.113, p=0.507) and 25 (OH)D serum in breast cancer patients.Conclusion: There were no significant correlations between BMI and vitamin D intake with 25(OH)D serum in breast cancer patients. Further study is required on the effect of chemotherapy regimens on vitamin D metabolism.


Sign in / Sign up

Export Citation Format

Share Document